JP2022515338A5 - - Google Patents

Info

Publication number
JP2022515338A5
JP2022515338A5 JP2021532368A JP2021532368A JP2022515338A5 JP 2022515338 A5 JP2022515338 A5 JP 2022515338A5 JP 2021532368 A JP2021532368 A JP 2021532368A JP 2021532368 A JP2021532368 A JP 2021532368A JP 2022515338 A5 JP2022515338 A5 JP 2022515338A5
Authority
JP
Japan
Prior art keywords
seq
promoter
nucleic acid
aav
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021532368A
Other languages
English (en)
Japanese (ja)
Other versions
JP7590968B2 (ja
JP2022515338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/064396 external-priority patent/WO2020117898A1/en
Publication of JP2022515338A publication Critical patent/JP2022515338A/ja
Publication of JP2022515338A5 publication Critical patent/JP2022515338A5/ja
Priority to JP2024177032A priority Critical patent/JP2025011200A/ja
Application granted granted Critical
Publication of JP7590968B2 publication Critical patent/JP7590968B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021532368A 2018-12-05 2019-12-04 遺伝子送達のための組み換えアデノ随伴ウイルスベクター Active JP7590968B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024177032A JP2025011200A (ja) 2018-12-05 2024-10-09 遺伝子送達のための組み換えアデノ随伴ウイルスベクター

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862775871P 2018-12-05 2018-12-05
US62/775,871 2018-12-05
US201962801195P 2019-02-05 2019-02-05
US62/801,195 2019-02-05
US201962863126P 2019-06-18 2019-06-18
US62/863,126 2019-06-18
US201962914856P 2019-10-14 2019-10-14
US62/914,856 2019-10-14
PCT/US2019/064396 WO2020117898A1 (en) 2018-12-05 2019-12-04 Recombinant adeno-associated viral vector for gene delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024177032A Division JP2025011200A (ja) 2018-12-05 2024-10-09 遺伝子送達のための組み換えアデノ随伴ウイルスベクター

Publications (3)

Publication Number Publication Date
JP2022515338A JP2022515338A (ja) 2022-02-18
JP2022515338A5 true JP2022515338A5 (cg-RX-API-DMAC7.html) 2022-12-12
JP7590968B2 JP7590968B2 (ja) 2024-11-27

Family

ID=70974857

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532368A Active JP7590968B2 (ja) 2018-12-05 2019-12-04 遺伝子送達のための組み換えアデノ随伴ウイルスベクター
JP2024177032A Pending JP2025011200A (ja) 2018-12-05 2024-10-09 遺伝子送達のための組み換えアデノ随伴ウイルスベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024177032A Pending JP2025011200A (ja) 2018-12-05 2024-10-09 遺伝子送達のための組み換えアデノ随伴ウイルスベクター

Country Status (11)

Country Link
US (1) US12454701B2 (cg-RX-API-DMAC7.html)
EP (1) EP3890786A4 (cg-RX-API-DMAC7.html)
JP (2) JP7590968B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220022107A (cg-RX-API-DMAC7.html)
CN (1) CN113423434A (cg-RX-API-DMAC7.html)
AU (1) AU2019391042A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021009913A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121177A1 (cg-RX-API-DMAC7.html)
IL (1) IL283546A (cg-RX-API-DMAC7.html)
MX (1) MX2021006646A (cg-RX-API-DMAC7.html)
WO (1) WO2020117898A1 (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018281280B2 (en) 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
EP3860659A1 (en) 2018-10-01 2021-08-11 The Trustees of the University of Pennsylvania Compositions useful for treating gm1 gangliosidosis
BR112021009913A2 (pt) * 2018-12-05 2021-08-17 Abeona Therapeutics, Inc. vetor viral adeno-associado recombinante para inserção gênica
EA202192328A1 (ru) * 2019-03-22 2022-02-21 Раш Юниверсити Медикал Сентер Комбинация назальной доставки генов и пероральной доставки коричной кислоты, олеамида или гемфиброзила для лечения лизосомных болезней накопления
US20210082541A1 (en) * 2019-08-31 2021-03-18 Wyatt Technology Corporation Measuring attributes of a viral gene delivery vehicle sample via separation
CN113025618B (zh) * 2019-12-24 2024-02-06 朗信启昇(苏州)生物制药有限公司 一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
FI4103214T3 (fi) 2020-02-13 2026-07-03 Tenaya Therapeutics Inc Geeniterapian vektorit sydänsairauden hoitoon
WO2021183895A1 (en) * 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
CA3175905A1 (en) * 2020-04-27 2021-11-04 David H. Kirn Codon optimized gla genes and uses thereof
CN115552021A (zh) 2020-04-27 2022-12-30 4D分子治疗有限公司 用于肺递送的腺相关变体、制剂和方法
GB202010981D0 (en) * 2020-07-16 2020-09-02 Ucl Business Ltd Gene therapy for neuromuscular and neuromotor disorders
JP2023540098A (ja) * 2020-09-03 2023-09-21 チェン アーヴィン エス.ワイ. 可溶性アルカリホスファターゼ構築物及び可溶性アルカリホスファターゼ構築物をコードするポリヌクレオチドを含む発現ベクター
CN114507692B (zh) * 2020-11-16 2024-07-12 舒泰神(北京)生物制药股份有限公司 用于治疗法布里病的腺相关病毒载体及其用途
WO2022100748A1 (en) * 2020-11-16 2022-05-19 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof
PE20240915A1 (es) * 2021-01-14 2024-04-30 Spark Therapeutics Inc Composiciones y metodos para tratar la enfermedad de fabry
AR124981A1 (es) * 2021-02-26 2023-05-24 Takeda Pharmaceuticals Co Composición y métodos para el tratamiento de la enfermedad de fabry
EP4340856A4 (en) * 2021-05-18 2025-06-04 Abeona Therapeutics Inc. Methods and compositions for treating eye diseases and conditions
TW202317768A (zh) 2021-07-08 2023-05-01 美商特納亞治療股份有限公司 用於基因療法的優化表現卡匣
WO2023284873A1 (en) * 2021-07-15 2023-01-19 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant adeno-associated viral vectors for treating bietti crystalline dystrophy
EP4392569A4 (en) * 2021-08-25 2025-07-16 Canbridge Pharmaceuticals Inc AAV PARTICLES COMPRISING A LIVER-TROPIC CAPSID PROTEIN AND AN ALPHA-GALACTOSIDASE AND THEIR USE FOR TREATING FABRY DISEASE
WO2023028567A2 (en) * 2021-08-25 2023-03-02 Canbridge Pharmaceuticals, Inc. Aav particles comprising a liver-tropic capsid protein and acid alpha-glucosidase (gaa) and their use to treat pompe disease
CN114181318B (zh) * 2021-11-08 2023-08-01 四川大学 一种组织特异性表达穿透血脑屏障的idua融合蛋白的重组腺相关病毒及应用
AU2022388800A1 (en) * 2021-11-12 2024-06-27 The Trustees Of The University Of Pennsylvania Gene therapy for treatment of mucopolysaccharidosis iiia
CN118028318A (zh) * 2021-12-22 2024-05-14 苏州诺洁贝生物技术有限公司 优化的cyp4v2基因及其用途
JP2025516136A (ja) * 2022-04-19 2025-05-27 シャンハイ ヴァイタルゲン バイオファーマ カンパニー リミテッド 神経変性疾患の治療のための組み換えaavベクター
CN115029360B (zh) * 2022-05-30 2024-08-02 上海勉亦生物科技有限公司 用于治疗粘多糖贮积症iiia型的转基因表达盒
WO2023240236A1 (en) * 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
AU2023288029A1 (en) * 2022-06-21 2025-02-13 Skyline Therapeutics Limited Recombinant aav for the gene therapy of sma disease
KR20240000814A (ko) * 2022-06-24 2024-01-03 연세대학교 산학협력단 망막색소상피에 특이적으로 작동하는 CRISPR/Cas 복합체를 유효성분으로 포함하는 망막질환 치료용 약학조성물
JP2025525583A (ja) 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性dnaベクター
WO2024054864A1 (en) 2022-09-06 2024-03-14 Tenaya Therapeutics, Inc. Cardioprotective heart disease therapies
CN121406674A (zh) * 2022-10-08 2026-01-27 凌意(杭州)生物科技有限公司 用于治疗GCase缺乏相关疾病的多核苷酸
CN115960177B (zh) * 2022-10-09 2023-07-07 广州派真生物技术有限公司 腺相关病毒突变体及其应用
KR20240086741A (ko) * 2022-11-28 2024-06-19 (주)지뉴인텍 Pde6b 유전자가 포함된 아데노연관바이러스 재조합 벡터를 유효성분으로 포함하는 유전성 망막질환 예방 또는 치료용 조성물
IT202300004443A1 (it) * 2023-03-09 2024-09-09 Int Centre For Genetic Engineering And Biotechnology Icgeb Sequenza codificante per alfa galattosidasi a umana per il trattamento della malattia di fabry
WO2024215655A1 (en) 2023-04-10 2024-10-17 Tenaya Therapeutics, Inc. Cardioprotective bag3 therapies
EP4695396A1 (en) 2023-04-10 2026-02-18 Tenaya Therapeutics, Inc. Guide rnas, vectors, and virions for targeting mutations in the pln gene
CN121002183A (zh) * 2023-04-17 2025-11-21 杭州复因生物科技有限公司 用于基因治疗的组合物和方法
EP4704920A1 (en) * 2023-05-04 2026-03-11 Abeona Therapeutics Inc. Recombinant adeno-associated viral vectors for multipartite gene delivery and stargardt disease treatment
WO2024233669A2 (en) * 2023-05-11 2024-11-14 Saliogen Therapeutics, Inc. Compositions and methods for treatment of cystic fibrosis
EP4711461A1 (en) * 2023-05-12 2026-03-18 Genecombio Ltd. Viral vector carrying smn gene expression cassette and use thereof
CN116622750B (zh) * 2023-06-01 2024-05-31 上海勉亦生物科技有限公司 优化的人法布里转基因表达盒及其用途
KR20260025090A (ko) * 2023-06-09 2026-02-23 4디 몰레큘러 테라퓨틱스 아이엔씨. 아데노-연관 바이러스 제형
WO2025030426A1 (en) * 2023-08-09 2025-02-13 Chigenovo Co., Ltd. Pharmaceutical preparations for treating bietti's crystalline dystrophy
WO2025039622A1 (zh) * 2023-08-23 2025-02-27 上海金珂博生物技术有限公司 经修饰的腺相关病毒载体及其在治疗中枢神经系统疾病中的用途
WO2025090786A1 (en) * 2023-10-24 2025-05-01 Rampart Bioscience, Inc. Reduced immunogenic gene therapy protocols using circular, extended cruciform containing non-viral vectors
WO2025092951A1 (en) * 2023-11-03 2025-05-08 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant adeno-associated viral vectors for treating fabry disease
WO2026072721A1 (en) * 2024-09-25 2026-04-02 Carbon Biosciences, Inc. Parvovirus compositions and methods for gene therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101433D0 (sv) 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
WO2001036603A2 (en) 1999-11-17 2001-05-25 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
US7638120B2 (en) 2000-03-14 2009-12-29 Thomas Jefferson University High transgene expression of a pseudotyped adeno-associated virus type
JP2004514407A (ja) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10120265A1 (de) 2001-04-25 2002-11-14 Deutsches Krebsforsch AAV-Helferplasmide zur Helfervirus-freien Verpackung und Pseudotypisierung von AAV-Vektoren
EP1463805B1 (en) 2001-12-17 2014-10-22 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
JP4979067B2 (ja) 2003-05-01 2012-07-18 ジェンザイム・コーポレーション 神経代謝性疾患についての遺伝子治療
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US7527947B2 (en) 2004-06-14 2009-05-05 Novozymes A/S Signal peptide for producing a polypeptide
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
US7867484B2 (en) 2006-01-27 2011-01-11 University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
WO2007148971A2 (en) 2006-06-21 2007-12-27 Amsterdam Molecular Therapeutics B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
JP2010506838A (ja) * 2006-10-12 2010-03-04 コペルニクス セラピューティクス インコーポレイテッド コドン最適化cftr
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
US8632764B2 (en) 2008-04-30 2014-01-21 University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
DK2561073T3 (en) 2010-04-23 2016-12-12 Univ Massachusetts Aav vectors targeted to central nervous system and methods of use thereof
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
US10738326B2 (en) 2010-10-27 2020-08-11 Jichi Medical University Adeno-associated virus vector for gene transfer to nervous system cells
DK3693025T3 (da) * 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
IL287381B2 (en) * 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
WO2013174760A1 (en) 2012-05-25 2013-11-28 Deutsches Krebsforschungszentrum Optimized aav-vectors for high transduction rates in dendritic cells
PL2900686T3 (pl) 2012-09-28 2021-01-25 The University Of North Carolina At Chapel Hill Wektory aav ukierunkowane na oligodendrocyty
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
DK2986635T3 (en) * 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
US10577627B2 (en) * 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
AU2015349759B2 (en) 2014-11-21 2022-01-06 The University Of North Carolina At Chapel Hill Aav vectors targeted to the central nervous system
CA3012344A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
JP6994018B2 (ja) * 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド 新規アデノ随伴ウイルスキャプシドタンパク質
WO2018178067A1 (en) 2017-03-27 2018-10-04 Vrije Universiteit Brussel Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
WO2020018766A1 (en) 2018-07-20 2020-01-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Intraocular delivery of gene therapy expression vectors
BR112021009913A2 (pt) 2018-12-05 2021-08-17 Abeona Therapeutics, Inc. vetor viral adeno-associado recombinante para inserção gênica
EP4340856A4 (en) 2021-05-18 2025-06-04 Abeona Therapeutics Inc. Methods and compositions for treating eye diseases and conditions

Similar Documents

Publication Publication Date Title
US10369232B2 (en) Allele selective gene editing and uses thereof
JP2024095717A5 (cg-RX-API-DMAC7.html)
JP2021502060A5 (cg-RX-API-DMAC7.html)
JP7832262B2 (ja) 肝特異的ウイルスプロモーター及びその使用方法
CN114450031A (zh) 靶向rna的敲低和替代组合物及使用方法
JP2023534999A5 (cg-RX-API-DMAC7.html)
JP2022517174A5 (cg-RX-API-DMAC7.html)
JP2023535956A5 (cg-RX-API-DMAC7.html)
IL308514B1 (en) Aav treatment of huntington's disease
US12037588B2 (en) Compositions and methods comprising engineered short nuclear RNA (snRNA)
JP2022526021A5 (cg-RX-API-DMAC7.html)
JP2024523707A5 (cg-RX-API-DMAC7.html)
JP2023523622A5 (cg-RX-API-DMAC7.html)
RU2018145010A (ru) Оптимизированные гены и экспрессионные кассеты cln1, и их применение
KR20210096168A (ko) 신경퇴행성 질환을 위한 유전자 요법
JP2022512689A5 (cg-RX-API-DMAC7.html)
JP2021525531A5 (cg-RX-API-DMAC7.html)
IL279091B1 (en) Compositions and methods for treating dominant retinitis pigmentosa
JP2024519733A5 (cg-RX-API-DMAC7.html)
JP2024513907A5 (cg-RX-API-DMAC7.html)
JP2025521102A5 (cg-RX-API-DMAC7.html)
JP2024530023A5 (cg-RX-API-DMAC7.html)
JP2024541319A5 (cg-RX-API-DMAC7.html)
JP2025513066A5 (cg-RX-API-DMAC7.html)
JP2024519819A5 (cg-RX-API-DMAC7.html)